These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 11394505

  • 41. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.
    Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F.
    Cancer Res; 2007 Nov 01; 67(21):10556-63. PubMed ID: 17975000
    [Abstract] [Full Text] [Related]

  • 42. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M.
    Haematologica; 2006 Feb 01; 91(2):176-83. PubMed ID: 16461301
    [Abstract] [Full Text] [Related]

  • 43. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
    Ravindranath NM, Nishimoto K, Chu K, Shuler C.
    Anticancer Res; 2000 Feb 01; 20(1A):21-6. PubMed ID: 10769630
    [Abstract] [Full Text] [Related]

  • 44. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 45. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
    Mattila AM, Meri S.
    Scand J Immunol; 2008 Aug 18; 68(2):159-68. PubMed ID: 18702746
    [Abstract] [Full Text] [Related]

  • 46. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 18; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP.
    Semin Hematol; 2008 Apr 18; 45(2):126-32. PubMed ID: 18381108
    [Abstract] [Full Text] [Related]

  • 50. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.
    Cancer Immunol Immunother; 2002 Mar 18; 51(1):15-24. PubMed ID: 11845256
    [Abstract] [Full Text] [Related]

  • 51. Rituximab: an insider's historical perspective.
    Grillo-López AJ.
    Semin Oncol; 2000 Dec 18; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [Abstract] [Full Text] [Related]

  • 52. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR, Vega MI, Bonavida B.
    Cancer Res; 2007 Feb 01; 67(3):1270-81. PubMed ID: 17283164
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP, Anderson KC.
    Semin Oncol; 2000 Dec 01; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [Abstract] [Full Text] [Related]

  • 55. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.
    Clin Cancer Res; 2004 Dec 01; 10(23):7842-51. PubMed ID: 15585616
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I.
    Cell Immunol; 2000 Aug 25; 204(1):55-63. PubMed ID: 11006018
    [Abstract] [Full Text] [Related]

  • 59. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
    Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, Jung G, Martin D, Niethammer D, Lang P.
    Bone Marrow Transplant; 2005 Jul 25; 36(2):91-7. PubMed ID: 15908973
    [Abstract] [Full Text] [Related]

  • 60. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
    Markasz L, Vanherberghen B, Flaberg E, Otvös R, Stuber G, Gustafsson Jernberg A, Olah E, Skribek H, Szekely L.
    Biomed Pharmacother; 2009 Jul 25; 63(6):413-20. PubMed ID: 18834693
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.